Carmot Therapeutics
Berkeley, United States· Est.
Carmot Therapeutics employs a chemoproteomic discovery platform to identify novel small molecule drugs for metabolic diseases and oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $310M
About
Carmot Therapeutics employs a chemoproteomic discovery platform to identify novel small molecule drugs for metabolic diseases and oncology.
MetabolicOncologySmall Molecules
Funding History
2Total raised:$310M
Series D$150M
Series C$160M